Active, not recruitingPhase 3NCT00002462
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
Studying Tumor of hematopoietic and lymphoid tissues
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- John Raemaekers, MD, PhDUniversitair Medisch Centrum St. Radboud - Nijmegen
- Intervention
- bleomycin sulfate(biological)
- Enrollment
- 615 target
- Eligibility
- 15-70 years · All sexes
- Timeline
- 1989
Study locations (30)
- Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
- A.Z. St. Jan, Bruges, Belgium
- Hopital Universitaire Erasme, Brussels, Belgium
- C.H.U. Saint-Pierre, Brussels (Bruxelles), Belgium
- Institut Jules Bordet, Brussels (Bruxelles), Belgium
- Centre Hospitalier Universitaire Brugmann, Brussels (Bruxelles), Belgium
- Centre Hospitalier Universitaire de Tivoli, La Louvière, Belgium
- U.Z. Gasthuisberg, Leuven, Belgium
- U.Z. Sint-Rafael, Leuven, Belgium
- National Cancer Institute of Egypt, Cairo, Egypt
- Institut Bergonie, Bordeaux, France
- Centre Regional Francois Baclesse, Caen, France
- Centre Hospitalier General, Compiègne, France
- Centre Georges-Francois Leclerc, Dijon, France
- Centre Leon Berard, Lyon, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002462 on ClinicalTrials.govOther trials for Tumor of hematopoietic and lymphoid tissues
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07249346Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationHannah Choe, MD
- RECRUITINGPHASE1NCT06904066Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07270770BY002 IIT Study in R/R Acute LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07257419CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07249905Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaModeX Therapeutics, An OPKO Health Company
- RECRUITINGPHASE1, PHASE2NCT07471789Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).Gyala Therapeutics
- RECRUITINGNANCT07051525Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and FeverPeter MacCallum Cancer Centre, Australia
- RECRUITINGPHASE1NCT06441331Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsITM Solucin GmbH
See all trials for Tumor of hematopoietic and lymphoid tissues →